Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 3, 1999, Pages 327-332

  Stegmayr, Bernd ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute renal failure; Dialysis; Plasma exchange; Plasmapheresis; Sepsis; Therapy

Indexed keywords

BACTERIAL TOXIN; CYTOKINE; HEMOGLOBIN; MYOGLOBIN;

ADSORPTION; BLOOD FILTRATION; BLOOD LEVEL; CAUSE OF DEATH; CENTRIFUGATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; CRITICAL ILLNESS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HEMODIALYSIS; HUMAN; INTENSIVE CARE; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL;

HUMANS; MULTIPLE ORGAN FAILURE; PLASMAPHERESIS; SEPSIS;

BACTERIA (MICROORGANISMS);

EID: 0032919169     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.055     Document Type: Conference Paper

References (73)

1. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med 1992; 20:724-6.
2. Bone RC. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa [editorial; comment]. J Am Med Assoc 1995; 273:155-6.
3. Pinsky MR. Organ-specific therapy in critical illness: interfacing molecular mechanisms with physiological interventions. J Crit Care 1996; 11:95-107.
4. Rietschel ET, Wagner H. Pathology of septic shock, 1 ed. London: Springer, 1996.
5. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-7.
6. Österud B. Meningococcal septicemia: the use of plasma-pheresis or blood exchange and how to detect severe endotoxin induced white cell activation. Scand J Clin Lab Invest 1985; 45:47-51.
7. Woodrow G, Turney JH. Cause of death in acute renal failure. Nephrol Dial Transplant 1992; 7:230-4.
8. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-27.
9. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996; 11:293-9.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ system failure. Ann Surg 1985; 202:685-93.
11. Bone RC. Sepsis and SIRS. In: Papadimitriou M, Alexopoulos E, editors. Proc 3rd Int Symp on Acute Renal Failure. Thessaloniki: University Studio Press, 1993:146-52.
12. Bone RC. Let's agree on terminology: definitions of sepsis. Crit Care Med 1991; 19:973-6.
13. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemostasis 1980; 43:28-33.
14. Smithies MN, Cameron JS. Can we predict outcome in acute renal failure. Nephron 1989; 51:297-300.
15. Druml W, Lax F, Grimm G, Schneeweiss B, Lenz K, Laggner AN. Acute renal failure in the elderly 1975-1990. Clin Nephrol 1994; 41:342-9.
16. Cohen J, Cartel J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-40.
17. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-83.
18. Reinhart K, Wiegand LC, Grimminger F, Kaul M, Withington S, Treacher D, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study [see comments]. Crit Care Med 1996; 24:733-42.
19. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702.
20. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhlL-1ra Sepsis Syndrome Study Group [see comments]. Am Med Assoc 1994; 271:1836-43.
21. Knaus WA, Harrell FJ, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, et al. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhlL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24:46-56.
22. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-42.
23. Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JJ, Knaus WA, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. J Am Med Assoc 1997; 277:482-7.
24. Keane WF, Hirata DC, Bullock ML, Ney AL, Guay DR, Kalil RS, et al. Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. J Am Soc Nephrol 1991; 2:841-7.
25. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1994; 330:1107-13.
26. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60:1225-30.
27. Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996; 1:83-90.
28. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998; 133:94-100.
29. Slotman GJ, Fisher CJ, Bone RC, Clemmer TP, Metz CA. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1993; 21:191-5.
30. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature [see comments]. Crit Care Med 1995; 23:1430-9.
31. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone [see comments]. Crit Care Med 1998; 26:645-50.
32. Davies SP, Reaveley DA, Brown EA, Kox WJ. Amino acid clearances and daily losses in patients with acute renal failure treated by continuous arteriovenous hemodialysis. Crit Care Med 1991; 19:1510-5.
33. Bellomo R, Martin H, Parkin G, Love J, Kearley Y, Boyce N. Continuous arteriovenous haemodiafiltration in the critically ill: influence on major nutrient balances. Intensive Care Med 1991; 17(7): 399-402.
34. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993; 21(4): 522-6.
35. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48:1563-70.
36. Byrick RJ, Goldstein MB, Wong PY. Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 1992; 20:1483-6.
37. Dinarello CA. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. Kidney Int Suppl 1992; 38:568-77.
38. Klinkmann H, Falkenhagen D. Importance of endotoxins in high-flux dialysis [letter; comment]. Nephrol Dial Transplant 1992; 7:884-5.
39. Foret M, Hachache T, Meftahi H, Milongo R, Kuentz F, Christollet M, at al. The long-term evaluation of the biocompatibility of nine different haemodialysis membranes. Life Support Systems 1987; 5:203-6.
40. Stegmayr B, Esbensen K, Gutierrez A, Lundberg L, Nielsen B, Strømsæter CE, et al. Granulocyte elastase, β-thromboglobulin, and C3d during acetate or bicarbonate hemodialysis with Hemophan compared to a cellulose acetate membrane. Internat J Artif Organs 1992; 15:45-53.
41. Druml W. Nonrenal indications for continuous hemofiltration therapy in patients with normal renal function? Contrib Nephrol 1995; 116:121-9.
42. Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ. Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis. J Am Soc Nephrol 1993; 4:148-54.
43. Lang S, Kuchle C, Fricke H, Schiffl H. Biocompatible intermittent hemodialysis. New Horiz 1995; 3:680-7.
44. Himmelfarb J, Hakim RM. The use of biocompatible dialysis membranes in acute renal failure. Adv Ren Replace Ther 1997; 4 (2 Suppl 1):72-80.
45. Falkenhagen D, Brown GS, Winkler R, Holtz M, Mohrke T, Schneidewind J, et al. Possibilities of selective and unselective adsorbent development in blood purification. Contrib Nephrol 1990; 78:142-54.
46. Weber C, Henne B, Loth F, Schoenhofen M, Falkenhagen D. Development of cationically modified cellulose adsorbents for the removal of endotoxins. ASAIO J 1995-41: M430-4.
47. Weber C, Falkenhagen D. Extracorporeal removal of proinflammatory cytokines by specific absorption onto microspheres. ASAIO J 1996; 42(5): M908-11.
48. Tetta C, Cavaillon JM, Camussi G, Lonnemann FG, Brendolan A, Ronco C. Continuous plasma filtration coupled with sorbents. Kidney Int Suppl 1998; 66:S186-9.
49. Samtleben W, Bengsch S, Boos KS, Seidel D. HELP apheresis in the treatment of sepsis. Artif Organs 1998; 22:43-6.
50. Tani T, Hanasawa K, Kodama M. [Usefulness of endotoxin removal from the septic blood with direct hemoperfusion using PMX-F]. Nippon Geka Gakkai Zasshi. Jpn Surgical Soci 1989; 90:1370-3.
51. Jaber BL, Pereira BJ. Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997; 30 (5 Suppl 4): S44-56.
52. Jaber BL, Barrett TW, Cendoroglo NM, Sundaram S, King AJ, Pereira BJ. Endotoxin removal by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma. ASIO J 1998; 44:54-61.
53. Doig GS, Martin CM, Sibbald WJ. Polymyxin-dextran anti-endotoxin pretreatment in an ovine model of normotensive sepsis [see comments]. Crit Care Med 1997; 25:1956-61.
54. Zimmermann M, Busch K, Kuhn S, Zeppezauer M. Endotoxin adsorbent based on immobilized human serum albumin. In: Sattelite Conference on Recent Developments in the Diagnosis and Therapy of the Sepsis Syndrome, [abstract] Regensburg: University of Regensburg, 1998.
55. Stegmayr B, Tärnvik A. Complement activation In plasma exchange by single filtration and centrifugation and in cascade filtration. Blood Purif 1989; 7:10-15.
56. Falkenhagen D, Brown GS, Boettcher M, Falkenhagen U, Schmidt B, Gurland HJ, et al. Permeation of complement factors through high-flux dialyzers and plasma separation membranes. In: Bambauer R, Malchesky PS, Falkenhagen D, editors. Therapeutic plasma exchange and selective plasma separation. Stuttgart: Schattauer, 1987:215-222.
57. Kotitschke R, Borberg H, Güsken G. Long-term study of the protein profiles in healthy volunteers after plasma exchange. In: Bambauer R, Malchesky PS, Falkenhagen D, editors. Therapeutic plasma exchange and selective plasma separation. Stuttgart: Schattauer, 1987:199-204.
58. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180:1025-35.
59. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181:1743-54.
60. Wurfel MM, Wright SD. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins. Prog Clin Biol Res 1995; 392:287-95.
61. Stegmayr B, Cedergren B, Nilsson T, Sondell K, Lindqvist B. On the use of liquid stored or cryoprecipitate-poor plasma in plasma exchange. In: Smeby LC, Jørstad S, Widerœ T-E, editors. Immune and metabolic aspects of therapeutic blood purification systems. Basel: Karger 1986:117-21.
62. Stegmayr B, Björck S, Holm S, Nisell J, Rydvall A, Settergren B. Septic shock induced by group A streptococcal infection clinical and therapeutic aspects. Scand J Infect Dis 1992; 24: 589-97.
63. Stegmayr BG. Plasma exchange in patients with septic shock including acute renal failure. Blood Purif 1996: 14:102-8.
64. Graf N, Bambauer R, Limbach HG. Indications, application and appraisal of therapeutic plasma exchange in children. In: Bambauer R, Malchesky PS, Falkenhagen D, editors. Therapeutic plasma exchange and selective plasma separation. Stuttgart: Schattauer, 1987:267-73.
65. Häuser W, Christmann F-J, Klein T, Traut G. Therapeutic plasma exchange in septic shock. In: Bambauer R, Malchesky PS, Falkenhagen D, editors. Therapeutic plasma exchange and selective plasma separation. Stuttgart: Schattauer, 1987:287-93.
66. McClelland P, Williams PS, Yaqoob M, Mostafa SM, Bone JM. Multiple organ failure - a role for plasma exchange? Intensive Care Med 1990; 16:100-3.
67. Bjorvatn B, Bjertnaes L, Fadnes HO, Flaegstad T, Gutteberg TJ, Kristiansen B-E, et al. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J 1984; 288:439-41.
68. Asanuma Y, Takahashi T, Koyama K, Kato T, Omokawa S, Sueoka A, et al. Exchange blood transfusion and on-line plasma exchange for sepsis in infants. ASAIO Trans 1989; 35:343-5.
69. Drapkin MS, Wisch JS. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J 1989; 8:399-400.
70. Berlot G, Tomasini A, Silvestri L, Gullo A. Plasmapheresis in the critically ill patient. Kidney Int Suppl 1998; 66:S178-81.
71. Kumar A, Kanagasundaram NS, Collyns TA, Davison AM. Plasma exchange and haemodiafiltration in fulminant meningococcal sepsis. Nephrol Dial Transplant 1998; 13:484-7.
72. Stegmayr BG, Norda R, Banga R, Rydvall A. Plasma exchange may improve survival of patients with multiorgan dysfunction syndrome including acute renal failure. Intensive Care Med 1998; 24:S89.
73. Rydvall A, Brändström A-K, Banga R, Asplund K, Bäcklund U, Stegmayr BG. Decreased serum cortisol in intensive care patients. Intensive Care Med 1998; 24:S88.